Lonnel Coats 의 보수는 Lexicon Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$194m
Dec 31 2023	US$4m	US$741k	-US$177m
Sep 30 2023	n/a	n/a	-US$158m
Jun 30 2023	n/a	n/a	-US$131m
Mar 31 2023	n/a	n/a	-US$110m
Dec 31 2022	US$4m	US$710k	-US$102m
Sep 30 2022	n/a	n/a	-US$97m
Jun 30 2022	n/a	n/a	-US$97m
Mar 31 2022	n/a	n/a	-US$90m
Dec 31 2021	US$4m	US$689k	-US$88m
Sep 30 2021	n/a	n/a	-US$68m
Jun 30 2021	n/a	n/a	US$38m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$4m	US$669k	-US$59m
Sep 30 2020	n/a	n/a	-US$104m
Jun 30 2020	n/a	n/a	US$39m
Mar 31 2020	n/a	n/a	US$85m
Dec 31 2019	US$4m	US$649k	US$130m
Sep 30 2019	n/a	n/a	US$164m
Jun 30 2019	n/a	n/a	-US$89m
Mar 31 2019	n/a	n/a	-US$101m
Dec 31 2018	US$3m	US$634k	-US$121m
Sep 30 2018	n/a	n/a	-US$126m
Jun 30 2018	n/a	n/a	-US$129m
Mar 31 2018	n/a	n/a	-US$130m
Dec 31 2017	US$2m	US$618k	-US$123m

보상 대 시장: Lonnel 의 총 보상 ($USD 4.11M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.43M ).

보상과 수익: Lonnel 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Lonnel Coats (59 yo)

10yrs

테뉴어

US$4,110,121

보상

Mr. Lonnel Coats serves as Independent Director of Verve Therapeutics, Inc. since August 08, 2022. He has been the Chief Executive Officer of Lexicon Pharmaceuticals, Inc., since July 7, 2014. He was Presi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Lonnel Coats	CEO & Director	10yrs	US$4.11m	0.30% $ 1.8m
Jeffrey Wade	President & CFO	14.2yrs	US$1.96m	0.090% $ 544.7k
Brian Crum	Senior VP	14.2yrs	US$1.42m	0.049% $ 298.2k
Alan Main	Executive Vice President of Innovation & Chemical Sciences	23yrs	US$1.39m	0.071% $ 429.6k
Craig Granowitz	Senior VP & Chief Medical Officer	2.9yrs	US$1.53m	0.013% $ 80.0k
Kristen Alexander	Vice President of Finance & Accounting	2.8yrs	데이터 없음	0.013% $ 80.3k
Lisa DeFrancesco	Head of Investor Relations & Corporate Strategy	less than a year	데이터 없음	데이터 없음
Dixon Terry	Vice President of Compliance	2.4yrs	데이터 없음	데이터 없음
Carrie Siragusa	Vice President of Marketing	1.1yrs	데이터 없음	데이터 없음
Desiree Gendron	Vice President of Sales & Training	no data	데이터 없음	데이터 없음
Wendy McDermott	Vice President of Human Resources	2.5yrs	데이터 없음	0.015% $ 88.5k
Kenneth Kassler-Taub	Senior Vice President of Regulatory Affairs & Quality Assurance	2.8yrs	US$1.48m	0.045% $ 273.3k

2.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: LXRX 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lonnel Coats	CEO & Director	10yrs	US$4.11m	0.30% $ 1.8m
Raymond Debbane	Independent Chairman of the Board	16.9yrs	US$127.82k	0.37% $ 2.3m
Samuel Barker	Independent Director	24.3yrs	US$117.46k	0.024% $ 147.3k
Philippe Amouyal	Independent Director	16.9yrs	US$100.52k	0.069% $ 417.3k
Robert Lefkowitz	Independent Director	23.4yrs	US$94.96k	0.013% $ 81.3k
Christopher Sobecki	Independent Director	16.9yrs	US$89.96k	0.046% $ 280.6k
Judith Swain	Independent Director	16.8yrs	US$104.96k	0.013% $ 81.3k
Alan Nies	Chairman of Medical Advisory Board	21.3yrs	US$82.87k	0.011% $ 68.9k
Diane Sullivan	Independent Director	less than a year	US$176.42k	데이터 없음

16.9yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: LXRX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 16.8 년).

Lexicon Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

CEO & Director exercised options and sold US$161k worth of stock

Independent Director recently bought US$202k worth of stock

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Independent Chairman of the Board recently bought US$1.1m worth of stock

Recent updates

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $62.204233 million.

Lexicon Pharmaceuticals, Inc. Announces Fda Approval of Inpefa™ (Sotagliflozin) for Treatment of Heart Failure

Consensus revenue estimates increase by 31%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS and revenues miss analyst expectations

CEO & Director exercised options and sold US$111k worth of stock

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Lexicon Pharmaceuticals, Inc. Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

Price target decreased to US$8.00

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. Announces New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

Lexicon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Lexicon Phmaceuticals, Inc. Announces That New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events

Lexicon Pharma: Key Regulatory Event In May 2023

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Lexicon Pharmaceuticals, Inc. Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

Lexicon announces FDA review of heart failure therapy

Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win

Price target increased to US$12.50